Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2019 8
2020 7
2021 10
2022 6
2023 10
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study.
Yuan Y, Egelston C, Colunga Flores O, Chaurasiya S, Lin D, Chang H, Chong LMO, Seiz A, Shah M, Meisen WH, Tang A, Martinez N, Pickett W, Murga M, Yost SE, Stewart D, Zhang J, Ede N, Modi B, Kessler J, Rand J, Fong Y. Yuan Y, et al. Among authors: yost se. Ther Adv Med Oncol. 2023 Nov 10;15:17588359231210675. doi: 10.1177/17588359231210675. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028143 Free PMC article.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: yost se. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Waisman J, Patel N, Vora L, Tumyan L, Bozoghlanian M, Stewart D, Frankel PH. Yuan Y, et al. Among authors: yost se. Oncologist. 2023 Jul 5;28(7):e498-e507. doi: 10.1093/oncolo/oyad026. Oncologist. 2023. PMID: 37023705 Free PMC article. Clinical Trial.
Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer.
Mahin D, Lavasani SM, Cristobal L, Tank Patel N, Sedrak M, Stewart D, Waisman J, Yuan Y, Yu W, Samoa R, Ruel N, Yost SE, Lee H, Kil SH, Mortimer JE. Mahin D, et al. Among authors: yost se. J Clin Med. 2023 Feb 28;12(5):1906. doi: 10.3390/jcm12051906. J Clin Med. 2023. PMID: 36902693 Free PMC article.
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Lavasani SM, et al. Among authors: yost se. Cancer. 2023 Mar 1;129(5):740-749. doi: 10.1002/cncr.34589. Epub 2022 Dec 14. Cancer. 2023. PMID: 36517940 Free PMC article. Clinical Trial.
38 results